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Abstract
Results of medical research studies are often contradictory or cannot be reproduced. One reason is that there may not be
enough patient subjects available for observation for a long enough time period. Another reason is that patient populations
may vary considerably with respect to geographic and demographic boundaries thus limiting how broadly the results apply.
Even when similar patient populations are pooled together from multiple locations, differences in medical treatment and
record systems can limit which outcome measures can be commonly analyzed. In total, these differences in medical
research settings can lead to differing conclusions or can even prevent some studies from starting. We thus sought to create
a patient research system that could aggregate as many patient observations as possible from a large number of hospitals
in a uniform way. We call this system the ‘Shared Health Research Information Network’, with the following properties: (1)
reuse electronic health data from everyday clinical care for research purposes, (2) respect patient privacy and hospital
autonomy, (3) aggregate patient populations across many hospitals to achieve statistically significant sample sizes that can
be validated independently of a single research setting, (4) harmonize the observation facts recorded at each institution
such that queries can be made across many hospitals in parallel, (5) scale to regional and national collaborations. The
purpose of this report is to provide open source software for multi-site clinical studies and to report on early uses of this
application. At this time SHRINE implementations have been used for multi-site studies of autism co-morbidity, juvenile
idiopathic arthritis, peripartum cardiomyopathy, colorectal cancer, diabetes, and others. The wide range of study objectives
and growing adoption suggest that SHRINE may be applicable beyond the research uses and participating hospitals named
in this report.
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Introduction
Results of medical research studies are often contradictory[1,2]
or cannot be reproduced[3,4,5,6,7]. One reason is that there may
not be enough available patient subjects[8] observed over a long
enough time period[9,10]. Another reason is that patient
populations may vary considerably across geographic[11] and
demographic boundaries[12] thus limiting how broadly the results
apply. Even when similar patient populations are pooled together
from multiple locations, differences in medical treatment[13] and
record systems[14,15] can limit which outcome measures can be
commonly analyzed. In total, these differences in medical research
settings can lead to differing conclusions or can even prevent some
studies from starting.
Consider Acute Lymphoblastic Leukemia (ALL), a rare
pediatric cancer. Since each hospital only sees a few cases per
year, studies of clinical effectiveness or disease biology are only
realistically possible through multi-center analyses[16]. Now
consider type 2 diabetes, a common polygenic disease having
many risk factors[17] and comorbid diagnoses[18,19]. The
number of adults in the United States with newly diagnosed
diabetes has more than tripled since 1980 [20] affecting patient
populations at different rates[21] among states [11], ethnicities
[12], and socioeconomic positions[12]. Grouping populations of
diabetic patients according to demographics, disease risk, and
previous treatments results in many smaller sets of patients to
analyze. Thus, even for a disease reaching epidemic levels it is
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to study enough patients representing the general population.
We thus sought to create a patient research system that could
aggregate as many patient observations as possible from as many
hospitals as possible. We call this system the ‘Shared Health
Research Information Network’, with the following properties: (1)
reuse electronic health data from everyday clinical care for
research purposes; (2) respect patient privacy and hospital
autonomy; (3) aggregate patient populations across many hospitals
to achieve statistically significant sample sizes that can be validated
independently of a single research setting; (4) harmonize the
observation facts recorded at each institution such that queries can
be made across many hospitals in parallel; (5) scale to regional and
national collaborations.
The purpose of this report is to provide open source
software[22] for multi-site clinical studies and to report on early
uses of this application. At this time SHRINE implementations
have been used for multi-site studies of autism co-morbidity[23],
juvenile idiopathic arthritis[24], peripartum cardiomyopathy[25],
colorectal cancer, diabetes[26], and likely others. The wide range
of study objectives and growing adoption of the software suggest
that SHRINE may be applicable beyond the research uses and
participating hospitals named in this report.
Results
SHRINE has been developed and deployed to at least six
networks in the United States serving a wide range of study
interests (Table 1). On the east coast, 5 Harvard affiliated teaching
hospitals are now able to query and analyze anonymized data on
over 6 million patients covering a 10 year period. Authorized
investigators perform Boolean searches for patient populations
matching detailed study criteria including patient demographics,
diagnoses, medications, and common lab tests. The east coast
network at Harvard has been used to conduct the largest study to
date of co-morbidities in Autism Spectrum Disorders[23]. The
Harvard network was also used to help validate a novel discovery
in peripartum cardiomyopathy[25], Many other population scale
studies are now possible for 7500+ authorized Harvard users. On
the west coast, 3 independent academic medical centers have
utilized SHRINE for an evaluation study focused on Type II
Diabetes[26]. Nationally, SHRINE has been used to link 61 health
institutions to create the largest US patient registry of pediatric
rheumatic diseases[24,27]. Another national SHRINE project is in
development spanning 9 large US institutions for studies of autism
and diabetes. In Europe, a consortium spanning 5 countries is
evaluating the use of SHRINE for use in clinical trials and
medication safety[28,29]. The research objectives, policy agree-
ments, and technical systems of each SHRINE network exhibit a
high degree of heterogeneity, suggesting that this approach is
broadly applicable for a wide range of patient studies.
Availability
SHRINE is freely available Open Source Software [22].
Methods
I. Design and Implementation
The goal of SHRINE is to query large, independent patient
populations to address problems of insufficient sample size and
sample bias. SHRINE is designed to reuse information captured
during patient care[30,31], to protect patient privacy[32], to query
heterogeneous health systems simultaneously, and to scale to
nation-wide participation[33]. SHRINE aims to serve multiple
study needs such as cohort discovery[34] and population scale
measurements[35,36].
The proof of concept system at Harvard was implemented
during Summer 2008 with a single year of patient demographic
and diagnosis data with access limited to users responsible for
building and demonstrating the system[37]. The production peer-
to-peer (P2P) system has since been developed and provides
federated user identity, asynchronous query broadcast and
aggregation, scalable network topologies, and tools for mapping
between medical concept coding systems.
II. Investigator Scenario
An Investigator at Children’s Hospital Boston is interested in
finding patients with Acute Lymphoid Leukemia (ALL) to study
the effectiveness of different chemotherapeutic agents in children
and adults (Figure 1). Because the incidence of ALL is rare, she
needs to aggregate patients from many hospitals to achieve
statistical significance. She applies for access to SHRINE, which
certifies that she is a qualified faculty member of a participating
hospital and has received query approval from the local Data
Steward. Her query for ‘Acute Lymphoid Leukemia’ (with or
without mention of remission) is then broadcasted to each one of
the participating hospitals and she is returned the aggregated
patient sets. She further refines her query to only include patients
treated with a multidrug chemotherapy regimen, as well as a
complete blood count test to confirm the ALL diagnoses. She then
requests IRB approval for access to the identified patient cohort.
Using SHRINE, she finds potentially five times as many patients
than if she looked only at a single hospital. Importantly, the
aggregated cohort contains both pediatric and adult cases
necessary to conduct this leukemia study.
III. Federated Query Sequence
From the investigator user perspective, SHRINE queries
multiple hospitals at the same time and aggregates results that
match the study criteria (Figure 1). From the system perspective,
SHRINE is a peer-to-peer (P2P) network of independently
controlled ‘peer’ databases. In SHRINE, there is no centralized
authority or centralized database – each hospital verifies their own
investigator employees, protects their own patient subjects, and
hosts their own database of observation facts.
First, the investigator must login to the hospital that employs
them. All investigator queries are digitally ‘signed-by’ their
employer in accordance with policy agreements. Second, the
investigator composes a query that conforms to the SHRINE Core
Ontology. The Core Ontology defines the standard set of medical
concepts and hierarchical relationships that can be used to
compose a query. Third, the query is broadcasted to each ‘peer’
hospital. Every hospital peer must have prior regulatory approvals
and business agreements. Fourth, each peer verifies that the
incoming query is from a trusted broadcaster and translates the
incoming query to be executed on the local patient data
repository. Fifth, each peer queries their local patient data
repository and anonymizes the query result. Finally, results are
aggregated and presented to the investigator (Figures 2 and Figure
S1).
The following sections describe how to compose a patient query
using standard medical ontologies, how to secure patient privacy,
how to prepare data mappings, how to translate federated queries,
and lastly, how to scale the network to nationwide participation.
IV. Composing a Patient Query
Patient queries are composed using concepts and relationships
defined in an ontology. The SHRINE Core Ontology supports many
SHRINE: Scalable Multi-Site Disease Studies
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medications, lab tests, and demographics (Table 2). The Core
Ontology contains 13,000+ diagnosis concepts and 4,500+ drug
ingredient concepts[38].
Hierarchical relationships[38,39] are used to organize the vast
number of medical concepts into groups that are easier for an
investigator to query and analyze. Consider heart disease, the
leading cause of death in the US[40]. Heart disease has many
billable conditions recorded during care delivery – 40 codes just
for various episodes and subtypes of heart attack (Acute
Myocardial Infarction). Patients with heart disease may also use
a beta-blocker, ACE inhibitor, or other cardiovascular medication.
Using the hierarchy makes it easier to query medically related
medications and diagnoses (Figure 3). SHRINE currently supports
a subset of the patient query features available in i2b2: Boolean
concept operators (and, or, not), hierarchical paths (query
expansion), and observation constraints (dates, number of occur-
rences).
Composing a patient query is usually an iterative process that
begins with a single large patient set and proceeds by analyzing
several smaller patient sets. First, an investigator may wish to see if
there are enough cases and controls to power their study. Second,
the investigator may refine the query criteria to additionally
require study features such as co-morbid diagnoses, medication
prescriptions, and lab tests. Third, the investigator may subdivide
patient sets according to age group, gender, or other demographic
Table 1. Deployed SHRINE networks.
Location # Institutions #Patients Research Focus
SHRINE East 5 6.1 M Any
National Disease Registry 61 ,5,000 Pediatric Rheumatic Diseases
National Demo 9 1.6 M+ Autism, Diabetes
California State 5 ,11 M Diagnoses, Procedures
SHRINE West 3 4.2 M+ Diabetes Epidemiology
The Harvard implementation (SHRINE east) is non-disease specific network used by faculty and fellows. Some studies have been completed and published. The National
disease registry is the largest disease registry in the US of its kind. The National Demonstration network is being used to analyzing co-morbidities of autism spectrum
disorders and diabetes in geographically disperse US states. Lastly, HMO SHRINE was a HMORN pilot project with 12 M+ patients. HMO SHRINE is not listed here
because the pilot was completed successfully.
doi:10.1371/journal.pone.0055811.t001
Figure 1. Investigator’s perspective of the SHRINE Webclient. Group 1 defines searches for patients with Acute Lymphoid Leukemia (ALL).
Group 2 refines the search result to only those patients having one of the medications listed. The medications shown are all chemotherapeutic agents
administered during intensive phase. Group 3 further refines the result to require a lab test administered during diagnosis. Lab test values can be set
directly or flagged as ‘abnormally high/low’. In the Query Status window, patient counts are displayed with a Gaussian blur to provide additional
privacy safeguards of small patient populations. Results are shown for each hospital and the aggregated patient set size.
doi:10.1371/journal.pone.0055811.g001
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their study objectives, receiving query answers in seconds that
would otherwise take days or even years to obtain.
V. Securing Patient Privacy
Hospitals are stewards of patient privacy. Striking the
balance between research benefit and disclosure risk is a
challenging responsibility for each hospital Institutional Review
Board (IRB). Given that each hospital is responsible for protecting
the privacy of their patients, it follows that each hospital should
retain the authority to approve or reject requests for access to data
on their patients. When the request comes from an investigator
employed by the hospital, it is reasonable to assume the hospital
knows who the investigator is and can verify her identity.
However, when the request is from an investigator at a different
hospital, how can the investigator be credentialed and trusted?
Technical solutions for building trust between hospital
peers. Trust agreements between collaborating SHRINE peer
Figure 2. Federate Query Sequence. The investigator logs in and composes a query in steps 1–2. SHRINE securely queries multiple hospital peers
and returns aggregated results in steps 3–6. The process of securing and translating queries across multiple hospitals is invisible to the investigator
user. Lastly, the investigator reviews the results and logs out in steps 7–8.
doi:10.1371/journal.pone.0055811.g002
Table 2. SHRINE Core Ontology.
CATEGORY CODING SYSTEM HIERARCHY
Diagnoses ICD-9-CM CCS2
Medications RxNorm NDF-RT
Lab Tests LOINC
Demographics
Gender HL7 Administrative Gender
Language ISO 639-1
Marital Status HL7 Marital Status
Race and Ethnicity CDC Race & Ethnicity Code Sets
Religion HL7 Religious Affiliation
Left column: categories supported in the core ontology include diagnoses,
medications, lab tests, and demographics. Middle column: coding system used
for each category. The demographics category uses multiple coding systems to
handle the relevant sub-categories such as gender and language. Right column:
hierarchy used to group medically related concepts. Standard hierarchies were
adopted where possible, which was the case for diagnoses and medications.
doi:10.1371/journal.pone.0055811.t002
Figure 3. Query Expansion in the Core Ontology. Selected
Example: ‘Cardiovascular medications’ is selected and the child contents
are shown. At runtime, the query is expanded to include every concept
in the cardiovascular medication group, recursively.
doi:10.1371/journal.pone.0055811.g003
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digital certificates. SHRINE uses digital certificates to secure
HTTPS communication and to identify hospital peers[41]. When
an investigator ‘logs-on’ at their hospital, the employing hospital
certifies the employee credentials and digitally signs the identity of
the investigator. The digital signature[42] is attached to the query
criteria before the query is sent (broadcast) to every trusted peer in
the network. When the query is received the source is verified
before processing. If the signature is from an untrusted source or if
the signature is invalid due to identity tampering, then the query is
rejected. Because digital signature verification is a local operation,
hospital credentialing systems do not need to be exposed to other
institutions.
To further protect against external hacking attempts, institu-
tional firewalls at each hospital are configured to allow only IP
addresses of trusted peer institutions. To further protect against
internal privacy accidents, population statistics should be used
until the time that individual patient facts are truly necessary for
the study. The default level of data access in SHRINE is
‘anonymized’ meaning that only the size of the patient set is
returned, not a line item list of patient details. SHRINE
anonymized results are further obfuscated to protect very small
populations (,10 patients). Accidental sharing of patient numbers
poses little or no risk to patient privacy. If additional permission
has been granted by the hospital IRB, additional data access may
be provided by the hospital to authorized investigators.
Joining the Network. Prior to joining a SHRINE network,
each hospital secures institutional and regulatory approval. This
includes an IRB review (which may be expedited if the SHRINE
queries are only for aggregate numbers of patients meeting
criteria). It also requires agreement on a set of operational
principles or ‘Business Rules’ by the leadership of participating
institutions. The Business Rules (those implemented at Harvard are
provided in Supporting Information) serve as the template to secure
approvals to share clinical data between health research institu-
tions. Under these agreements, each institutional team loads
medical facts into a locally controlled data repository that resides
behind the hospital firewall.
Ethics Statement. The Institutional Review Boards (IRB) of
the Beth Israel Deaconess Medical Center, Children’s Hospital
Boston, Dana-Farber Cancer Center, and Partners Health Care
representing Massachusetts General Hospital and Brigham and
Women’s Hospital individually approved use of their data for the
SHRINE network. The human studies committee (IRB) at
Harvard Medical School in its role as fund administrator also
reviewed and approved the SHRINE network. The regulatory
committee of the Harvard CTSA (catalyst) developed a set of
policies governing usage of the SHRINE network that was
approved by the senior research vice president at each participat-
ing institution. Informed consent was not necessary as only
aggregate numbers of patient attributes derived from medical
records were provided, a usage considered non-human research by
all IRBs.
VI. Mapping Heterogeneous Medical Coding Systems in
Multi-Site Studies
Ideally, every hospital would adopt the same standard set of
medical concepts and relationships to record patient observations.
However, different hospitals often have differing clinical informa-
tion systems, medical coding practices, service specialties, and
patient populations. Different investigator users and data manag-
ers often have differing perspectives on how clinical data should be
schematically represented and semantically queried. Accounting
for these differences can quickly exhaust the human resources
available. SHRINE aims to maximize the breadth of supported
research studies without requiring significant investment in human
expert curators.
Figure 4 illustrates the mapping scenario for a typical SHRINE
participating site. First, the hospital extracts patient observations
from various clinical databases into a locally controlled patient
data repository. Second, hospital data curators construct bipartite
graphs (key value pairs) for each of the four categories of clinical
concepts defined in the Core Ontology. Each bipartite graph
relates a set of local concepts to a set of standard concepts. Figure 5
contains mapping examples for lab tests and medications. Third,
medically related concepts are grouped and their relationships are
traversed using standard medical hierarchies. Fourth, the local
hospital is now able to translate the incoming query to use local
concept codes. Figure 6 reports the coverage of supported
medication and diagnoses concepts at four Harvard hospitals.
Figure S2 provides a screenshot of the software that enables the
mapping process.
VII. Adapting Network Queries for Local Execution
SHRINE Adapters are interfaces between the SHRINE network
and the local patient data repository[43]. The Adapter translates
incoming queries so that the query can be executed locally without
changing the data in the local repository. Each participating
SHRINE peer hosts an Adapter loaded with mappings that
support query terms in the ‘Core Ontology’.
SHRINE Adapters validate, audit, translate, and anonymize
queries. First, each Adapter validates that the query is from a
trusted source by validating digital signature of the investigator
identity[42]. Second, each Adapter audits the investigator to
ensure against suspicious query activity such as excessive queries
for the same small patient cohort. Third, the Adapter translates
the query concepts into a format recognizable by the local data
repository. Fourth, the Adapter anonymizes the patient count by
applying a Guassian filter accurate to within +/23 patients of the
actual result[44]. Lastly, each Adapter responds to the originating
SHRINE Broadcaster-Aggregator.
SHRINE provides a plug-in architecture allowing any data
repository to be used so long as it accepts SHRINE messages. By
default, SHRINE is configured to use the i2b2 data repository
because it is commonly used[28,45]. Institutions that use a third
party data repository can participate in SHRINE by implementing
the open messaging interface. Both the SHRINE[22] and i2b2[46]
software packages are freely available and Open Source.
VIII. Scaling to National Participation
Groups of SHRINE hospitals (peers) can be configured in peer-
to-peer (p2p) or hub-spoke network topologies (Figure 7). In a p2p
network, every peer has a link to every other peer. In relatively
small SHRINE networks, p2p topologies can be configured with a
few links. However, the number of direct links quickly grows with
the number of peers in a fully-meshed network (Figure 8). Because
each link requires a firewall rule and webservice URL, even a
modestly sized network of 10 peers would require 45 firewall
exceptions and 10 duplicate copies of routing information. In a
network of 60 institutions, a p2p (fully meshed) network would
require 1,770 firewall rules and 60 duplicate routing tables, which
could overburden network administrators. Instead, larger deploy-
ments are more often arranged in hub-spoke topologies, as
exemplified by the quickly deployed CARRAnet registry.
Similar to TCP/IP networks, SHRINE facilitates grouping
regional peers into subnetworks and then links them together. This
is highly desirable because communication networks typically
grow according to power law[47,48] naturally leading to
SHRINE: Scalable Multi-Site Disease Studies
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previously utilized for the SPIN human tissue network, linking 7
large independent medical centers into regional peer groups [33].
SHRINE peers can participate in many different studies with
many different institutions at the same time without changing the
source data. Multiple Adapter mappings can be loaded for
Figure 4. Hospital Data Mapping Scenario. First, existing clinical data are extracted into a locally controlled database for research. Second, each
local code is mapped to one or more standard concept codes, and vice versa. Third, related medical concepts are grouped using standard hierarchies
curated by medical experts. The bipartite graphs produced by this process enable bidirectional translation between concept systems. Fourth, adapt
the incoming query to use the local concept codes.
doi:10.1371/journal.pone.0055811.g004
Figure 5. Constructing Bipartite graphs to map concept systems. Left: Medications are mapped between Children’s Hospital Boston (blue)
and the RxNorm standard (green) if they share a drug ingredient. The hospital concept code for Acetaminophen is mapped to the RxNorm concept
code for Acetaminophen. Codeine also has one mapping. ‘Acetaminophen with Codeine’ has a mapping to RxNorm for each of its ingredients.
Patients recorded with the local concept ‘Acetaminophen with Codeine’ will match standard queries using any of the mapped RxNorm drug
ingredients. Right: Lab Test concepts are mapped between Children’s Hospital Boston (blue) and the LOINC standard (green). Bicarbonate and Blood
Urea Nitrogen are each mapped once. Other lab tests require a one-to-many mapping, for example, there are at least four different metabolic tests
for sodium (Na+) levels recorded in the Children’s Hospital Boston clinical systems.
doi:10.1371/journal.pone.0055811.g005
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(Table 2) was designed to provide maximal breadth of medical
concepts commonly available in Electronic Health Record (EHR)
systems. However, the core ontology does not describe data
collected outside the EHR setting, such as patient registries or
clinical trials. In such cases, it is necessary to adopt[49] or define
ontologies suitable to how the data are collected. Because
SHRINE translates the query rather than transforming the data,
multiple study-specific views can occur simultaneously without
source data duplication or transformation.
Discussion
In this era of ‘translational’ research[50,51], there is a growing
and critical need for systems that streamline clinical data access for
research while maintaining patient privacy and safety. Concur-
rently, the need for ever-larger cohort sizes[3,31] increasingly
necessitates crossing institutional boundaries between healthcare
and research organizations that individually have insufficient
numbers of patient-subjects. In reusing the by-products of routine
care delivery, SHRINE has capitalized on low cost cohort
identification with very large yields in terms of both number of
Figure 6. Percentage of Diagnosis and Medication concepts mapped for SHRINE queries at participating Harvard affiliated
teaching hospitals. Left: Percentage of ICD9-CM diagnoses concepts mapped to at least one diagnosis concept at the hospital. Right: Percentage
of RxNorm medication concepts mapped to at least one patient medication concept at the hospital.
doi:10.1371/journal.pone.0055811.g006
Figure 7. Peer Group configurations. Top: P2P networks are shown for the deployed West and East coast SHRINE networks with 3 and 4 peers
respectively. P2P networks have n*(n-1)/2 edges. In the example p2p network with 6 peers, 6*5/2=15 edges are drawn. A 60 node P2P network
would have 60*59/2=1,770 edges. Bottom: Hub Spoke networks are drawn starting with 6 peers. As peers are added, they can attach with a single
link to an existing hub. As new hubs are formed regionally, they can be easily attached to the overall network.
doi:10.1371/journal.pone.0055811.g007
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and whole networks are increasingly being instantiated for
population scale measurement on regional and national scales.
The widespread use and wide range of investigation scenarios
served suggest that there may be broader applicability for other
clinical research uses. Since SHRINE is more a network API
rather than a final product, it is possible to envision new
applications. For example, a European public-private partnership
is evaluating the SHRINE platform to locate patient cohorts for
clinical trials. There is also a strong potential for using SHRINE to
locate human biospecimens for genomic studies[31,52,53], mon-
itor population health [35,54], and detect adverse medication
events [36,55,56].
The authors recognize several limitations in this work. Limiting
results to patient counts was essential in the building phases to
reach agreement among hospital stakeholders. Consequently,
extracting clinical details on selected patients is currently a manual
process requiring IRB approval from each hospital and technical
assistance. The next major development of SHRINE will focus on
providing HIPAA Limited Data Sets on the subset of patients that
match an IRB approved query such that the application process is
streamlined for investigators.
Mapping medical concept dictionaries do not always produce
perfect translations between concept systems. In the case of patient
demographics and diagnoses, mappings were rather straight
forward as billing standards were already in place. In the case of
medications and lab results, mappings were much more difficult.
Future work with the NCBO[49] aims to improve and increasingly
automate our ability to map between coding systems.
Important study variables, such as smoking status[57,58], co-
morbidities[59], and family disease history[60] are often missing
from the coded record and more likely to appear in physician
notes. These variables can often be extracted[61,62] using Natural
Language Processing (NLP). A previous version of the SHRINE
federated query protocol worked in this way[33] by searching
pathology reports for human tissues[52] that matched coded
clinical criteria[63]. However, at the time of this writing, NLP
processing is not directly integrated into the SHRINE software.
The adoption of enterprise-wide NLP processing tools such as
cTAKES[62] may enable deeper and automatic extraction of data
contained in unstructured text.
Biases in patient populations, medical coding practices, and
records management directly influence which medical facts can be
uniformly studied and how the results are interpreted. As the
number of SHRINE participating peers and medical concepts
increase, so too does the burden on an investigator. In response,
we are exploring methods to empirically guide or ‘autosuggest’
features relevant to a particular disease study.
Figure 8. Quadratic growth in the number of edges in a communication network. Each edge incurs administrative overhead to maintain a
list of peer locations and trust relationships. Fully meshed peer-to-peer (P2P) topologies have N*(N-1)/2 edges shown in red. Edge growth of hub-
spoke topologies are shown with an average hub size of 3 (size of the first deployments of east and west coast networks). A simple hub-spoke
topology requires one additional link per hub, shown in green. A fault tolerant topology requires two additional links per hub, shown in purple. With
60 peers, the number of p2p edges is administratively infeasible with 1,770 firewall rules and trust relationships.
doi:10.1371/journal.pone.0055811.g008
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rapidly, SHRINE provides a scalable solution for querying the
informational byproducts of healthcare to conduct regional and
national disease studies. SHRINE seeks to overcome problems of
false discovery by 1) increasing the number of patients observed, 2)
validating results across many patient settings, and 3) capturing the
multitude of phenotypic characteristics observed during patient
care. SHRINE is now operational at many participating
institutions and is available open source. New institutions
interested in sharing clinical data can use the SHRINE software
and policy agreements, either in whole or in part (see Supporting
Information). Because there is no central database, regional
subnetworks and study specific collaborations are free to form
independent of any organizing body. Current uses of SHRINE are
primarily for locating patient cohorts and studying diseases at the
population scale, with the possibility for many more investigation
scenarios such as clinical trials preparation and genomic studies
involving human specimens.
Related Work. Several other research efforts have sought to
develop multi-site clinical research platforms. Each research
network is designed for a specific investigator scenario, such as
population health statistics[64], cancer informatics[65], biomedi-
cal imaging[66], and biomedical resource identification[66].
These efforts are also open source, with many years of shared
history formalizing the policy agreements and developing the
technical capabilities. Among these, SHRINE is most similar to
other distributed population query efforts[67]. Twelve distributed
population query systems (including SHRINE) are being inde-
pendently evaluated to achieve the objectives defined by the Office
of the National Coordinator, a complete comparison here is well
beyond the scope of this report.
As a general clinical data integration platform, SHRINE is
similar to other distributed query systems that use a mediated
schema[68]. Mapping mediated schemas to heterogeneous local
schemas is among the most challenging problems in computer
science (AI-complete)[69]. SHRINE query translation is essentially
synonym expansion, whereas other query mediators can fully
rewrite the query to the source system[70]. Defining concept
synonymy is often an easier problem to solve generally, suggesting
that SHRINE may be easier to implement than other systems that
provide more advanced query rewrite features.
Supporting Information
Figure S1 Federated Query Sequence. 1) Investigator starts
query with the provided user credentials and query criteria. 2–3)
Investigator credentials are certified and digitally signed. 4) Query
is broadcast to all trusted peers. 5–6) Each Adapter validates the
digitally signed identity and translates the criteria. 7) Each Adapter
queries their local Patient Data Repository. Most investigators will
only receive the patient set size (count). Some investigators
(national disease registry) can see additional data. 8–9) Results are
asynchronously aggregated. 10) Aggregated results shown to
investigator.
(TIFF)
Figure S2 Screenshot of Mapping Tool (SHRIMP). Left:
Children’s Hospital Boston Medication fragment is selected and
focused on propranolol (a beta blocker). Top Middle: concept details
including local key and name are displayed, which defines how this
medication is coded at CHB. Top Right: the local concept code for
propranolol is mapped to two core concepts: propranolol (the
brand name drug) and propranolol hydrochloride (the generic
drug). The hospital concept and the core concept refer to have the
same ingredient. Bottom: Users can quickly search the core
concepts to find mappings for the hospital concepts.
(TIFF)
Information S1 SHRINE Business Rules. This supporting
information includes a set of operating principles or ‘Business
Rules’ that were agreed upon by all institutions participating in the
Harvard network. The business rules can be used in whole or in
part to build agreement for new SHRINE networks.
(DOC)
Information S2 Technical Supporting Information. The
Technical Supporting Information describes requirements and
experiences using different data repositories and mapping different
medical coding systems. This SI also includes a list of SHRINE
query capabilities supported in the Core Ontology.
(DOCX)
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